FrankYounesLawyerReviews.com (402) 378-9208
Toxic Exposure · Nebraska & Iowa · Se habla español

Roundup Qualifying Cancers

The Roundup litigation compensates one family of cancers: non-Hodgkin lymphoma. But if that were the end of the answer, this page would not need to exist. “Non-Hodgkin lymphoma” is not a single disease — it is an umbrella over roughly seventy separately named blood cancers, and your pathology report almost certainly uses one of the specific names, not the umbrella. Every subtype below is on the qualifying list used in the litigation, as updated in February 2026. If any of these names — or any of the older names in parentheses — appears in your records or a family member’s, call me at (402) 378-9208 for a free case review, and read the Roundup claims page for how the rest of the case works.

Why the Name on Your Pathology Report Matters

Here is the conversation I have had too many times. Someone calls about a spouse’s leukemia, apologizes for bothering me, and says they assume Roundup cases are only for “lymphoma.” Then I ask what the pathology report says, they read me chronic lymphocytic leukemia, and I get to tell them that CLL is on the list — it is a non-Hodgkin lymphoma in everything but its everyday name. The naming of blood cancers is genuinely confusing: the same disease can be called a leukemia when it lives in the blood and a lymphoma when it lives in the nodes, diseases have been renamed repeatedly as classification systems evolved, and a diagnosis written in 1998 may use a term no oncologist would write today. That is why the list below includes the also-known-as names — the older labels that appear in older records — and why the only reliable way to answer “do I qualify?” is to read the actual words on the actual report.

Two housekeeping notes before the list. First, this page is legal information, not medical advice — your oncologist defines your diagnosis; my job is what the diagnosis qualifies for. Second, the list distinguishes aggressive from indolent subtypes. That is a clinical distinction about how the disease behaves — fast-moving versus slow-growing — and both categories qualify. It can affect how a claim is valued and handled, which is a conversation for the phone, not a reason to hesitate before calling.

Check Your Diagnosis

The fastest way to use this page: type any part of the diagnosis from your pathology report — “follicular,” “CLL,” “large B-cell,” “mantle” — and the list below will narrow to what matches, older names included.

Aggressive Subtypes on the Qualifying List

The fast-moving diseases — the ones that announce themselves and send you to treatment quickly. Diffuse large B-cell lymphoma, the most common non-Hodgkin lymphoma in adults, leads this category.

Indolent Subtypes on the Qualifying List

The slow-growing diseases — often found on routine bloodwork, sometimes watched for years before treatment. Do not let the gentler clinical course fool you into thinking these matter less legally: CLL/SLL and follicular lymphoma are among the most commonly diagnosed qualifying cancers in farm country.

How to Read the Fine Print in the List

A few markings above deserve translation. Where an entry carries a (WHO) or (ICC) tag, it means the diagnosis is named under one of the two modern classification systems pathologists use — the World Health Organization’s scheme or the International Consensus Classification — and your report may cite either; both count. Where an entry is qualified localized or high grade or other features present, the same disease appears in both halves of the list, sorted by how it presented — adult T-cell leukemia/lymphoma, mycosis fungoides and breast implant–associated lymphoma all straddle the line, qualifying either way. And the semicolons inside entries separate genuinely interchangeable names for one disease: if your report matches any name in an entry, it matches the entry. None of this fine print exists to trip patients — it exists because pathology reports span forty years of changing vocabulary, and the list is built to catch every version of the words.

The Diagnoses People Don’t Realize Count

A few entries above deserve to be pulled out of the list, because they are the ones qualifying Nebraskans most often dismiss:

What About Hodgkin Lymphoma, Myeloma, and Everything Else?

Honesty is the policy on this site, so: classical Hodgkin lymphoma is not on the qualifying list, and neither is multiple myeloma. One nuance matters, though — nodular lymphocyte predominant disease, which older records call “nodular lymphocyte predominant Hodgkin lymphoma,” has been reclassified by modern pathology as a B-cell lymphoma and is on the list. That is the single best illustration of why you should never disqualify yourself based on a disease name: a diagnosis with “Hodgkin” in its historical name qualifies because of what the disease actually is. And if your cancer is not on this list at all, a call may still be worth your time — other exposures carry other claims: asbestos and mesothelioma, benzene-linked leukemias, and the industrial and railroad occupational cancers I handle under different laws.

How to Find the Magic Words in Your Records

The document you want is the surgical pathology report — the report generated when your biopsy was read — and after it, the oncologist’s initial consultation note. Look for the line labeled “diagnosis” or “final diagnosis.” It will name the subtype, often with a WHO or ICC classification reference, sometimes with immunophenotype codes (CD20-positive, CD30, ALK) that also appear in the list above. If you cannot find the report, do not let that stop you from calling: you are entitled to your records, requests are routine, and I make them for my clients every week. For a family member who has died, the records survive and remain reachable — a personal representative can obtain them, and I help families do exactly that in wrongful-death reviews.

The Second Half of Qualifying: Exposure

The diagnosis is one pillar; Roundup exposure is the other. On this, one sentence here and the full story on the claims page: you did not have to be the person spraying — living beside sprayed fields, years around a treated golf course, park or campus, farm work near the product, and long-running home use can all qualify, and in Nebraska and Iowa that describes an enormous number of ordinary lives. Diagnosis from this page plus history like that equals a phone call worth making.

A Note on This List’s Currency

Blood-cancer classification is a moving target — the WHO and ICC systems continue to rename and split diagnoses, and the litigation’s qualifying list gets updated to follow. The version above reflects the February 2026 update, which is the current one as I write this. If your diagnosis sits near an edge — an unusual variant, a name you cannot find here, a report older than the modern classifications — do not adjudicate it yourself with a search engine. Read me the report. It costs nothing, it takes minutes, and being wrong in the cautious direction costs families real money.

Frank Younes, Nebraska Roundup qualifying cancers attorney

Your Attorney

Frank Younes

Every page on this site is written by Frank Younes, a Nebraska trial attorney with a published record of verdicts and settlements, selection to the National Trial Lawyers Top 100, and a practice that covers every county in Nebraska and Iowa. No case is handed to an associate — the lawyer you read here is the lawyer who works your case.

More about Frank → · Free consultation: (402) 378-9208

Frequently Asked Questions

My diagnosis says “leukemia,” not “lymphoma.” Am I excluded?

No — several leukemias are non-Hodgkin lymphomas by another name and are on the list: CLL, hairy cell leukemia, T-cell prolymphocytic leukemia, and the lymphoblastic leukemia/lymphomas among them. Read me the exact words on your pathology report.

Does classical Hodgkin lymphoma qualify?

No — classical Hodgkin lymphoma is not on the qualifying list. But nodular lymphocyte predominant disease, historically called a Hodgkin lymphoma, is now classified as a B-cell lymphoma and does appear on the list. Names mislead; reports decide.

My report just says “diffuse large B-cell lymphoma.” Is that enough?

Yes — DLBCL, NOS is on the list; it is the most common adult non-Hodgkin lymphoma. The next question is your exposure history, which the free review covers.

Do I need to know my subtype before calling?

No. “Non-Hodgkin lymphoma” from your doctor is enough to start, and I can obtain the pathology report that pins down the subtype. Do not let a missing document delay a phone call that is free.

Does it matter whether my subtype is aggressive or indolent?

Both categories qualify. The distinction describes the disease’s clinical behavior and can factor into how a claim is valued, but it is never a reason not to call.

I’m in remission. Do I still qualify?

Remission does not erase the diagnosis or the claim — you lived through the disease, its treatment and its costs. Timing rules still apply, so call sooner rather than later.

More on Toxic Exposure

The rest of the exposure series on this site.

← Toxic Exposure & Cancers
The main exposure page — every kind of case I handle, and how exposure cases are proven.
Roundup Cancer Claims
Who qualifies, why bystander and drift exposure counts, what the 2026 Supreme Court decision changed — and how to sign up.
After a Cancer Diagnosis: The Legal Checklist
Estate plan, powers of attorney, benefits — and the exposure-claim screening most patients never get.
Railroad Occupational Cancer
Diesel exhaust, creosote and solvents — cancer claims under FELA for rail workers.

Is Your Diagnosis on the List? Find Out Free

Free, confidential consultation — in English or Spanish. No fee unless I win.

Call (402) 378-9208

← Back to Roundup Cancer Claims

Get Your Free Consultation

No fee unless Frank wins. Tell him what happened — he'll personally follow up.

Prefer the phone? (402) 378-9208 — free and confidential.